ESSA Pharma Inc. (NASDAQ:EPIX) is Altium Capital Management LLC's 8th Largest Position

Key Points

• Altium Capital Management LLC reduced its stake in ESSA Pharma Inc. by 26.4%, now holding approximately 1,050,369 shares valued at $1,660,000.
• Other institutional investors, including Bank of America and BNP Paribas Financial Markets, have significantly increased their positions in ESSA Pharma during the fourth quarter.
• ESSA Pharma's stock currently trades at $1.91, with a market cap of $84.78 million and a 52-week range between $1.40 and $7.88.

Altium Capital Management LLC cut its holdings in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 26.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,050,369 shares of the company's stock after selling 377,631 shares during the quarter. ESSA Pharma accounts for 4.0% of Altium Capital Management LLC's investment portfolio, making the stock its 8th largest position. Altium Capital Management LLC owned about 2.37% of ESSA Pharma worth $1,660,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Squarepoint Ops LLC acquired a new position in shares of ESSA Pharma during the 4th quarter worth approximately $26,000. Two Sigma Securities LLC acquired a new position in shares of ESSA Pharma during the 4th quarter worth approximately $29,000. GTS Securities LLC acquired a new position in shares of ESSA Pharma during the 4th quarter worth approximately $30,000. Cubist Systematic Strategies LLC purchased a new stake in shares of ESSA Pharma during the fourth quarter worth approximately $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of ESSA Pharma during the fourth quarter worth approximately $67,000. 75.12% of the stock is owned by institutional investors and hedge funds.

ESSA Pharma Stock Performance

Shares of EPIX traded up $0.01 during trading hours on Friday, hitting $1.93. 217,663 shares of the stock were exchanged, compared to its average volume of 310,125. ESSA Pharma Inc. has a 12-month low of $1.40 and a 12-month high of $7.88. The company has a market cap of $85.67 million, a price-to-earnings ratio of -3.45 and a beta of 1.55. The stock's 50-day moving average price is $1.80 and its two-hundred day moving average price is $1.71.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, research analysts expect that ESSA Pharma Inc. will post -0.42 earnings per share for the current year.

ESSA Pharma Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.